Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HT-101 and HT-102 in Chronic Hepatitis B
NCT07917910Phase 2Not yet recruiting
- Sponsor
- Hepatera
- Start
- Oct 2026
- Primary completion
- Oct 2028
01
Overview
Phase 2, randomised trial in chronic hepatitis B virus infection (CHB) comparing HT-101 + HT-102 with HT-101 placebo + HT-102 placebo (2 arms). Primary endpoint: Proportion of participants achieving functional cure at 72 weeks. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
HT-101HT-102
03
Conditions
chronic hepatitis B virus infection (CHB)
Beyond the preview
Go deeper on NCT07917910.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07917910.